Considerations of Cost in Myeloma Care with Rafael Fonseca, MD of the Mayo Clinic, Scottsdale image

Considerations of Cost in Myeloma Care with Rafael Fonseca, MD of the Mayo Clinic, Scottsdale

Posted on: May 22, 2019
Play Episode
Also available on
Description

Rafael Fonseca, MD
Mayo Clinic Scottsdale
Interview Date: May 22, 2019

The cost of healthcare is on the minds of every stakeholder including patients, provider and payers, especially when it comes to cancer treatment. Dr. Rafael Fonseca joins Myeloma Crowd Radio to share his insights about the complexity of myeloma, factors that impact the development of innovation in myeloma and the focus on getting the proper care to patients as other economic interests are balanced in the process. Dr. Fonseca addresses what is sometimes called "STEP therapy" and how costs issues may need to be balanced with the  wholistic factors of great care.

Thanks to our episode sponsor

 

User uploaded media

 

Overview

Rafael Fonseca, MD
Mayo Clinic Scottsdale
Interview Date: May 22, 2019

The cost of healthcare is on the minds of every stakeholder including patients, provider and payers, especially when it comes to cancer treatment. Dr. Rafael Fonseca joins Myeloma Crowd Radio to share his insights about the complexity of myeloma, factors that impact the development of innovation in myeloma and the focus on getting the proper care to patients as other economic interests are balanced in the process. Dr. Fonseca addresses what is sometimes called "STEP therapy" and how costs issues may need to be balanced with the  wholistic factors of great care.

Thanks to our episode sponsor

 

User uploaded media

On this episode
Healthtree contact Rafael Fonseca, MD

Rafael Fonseca, MD

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, interim Executive Director of the Mayo Clinic Comprehensive Cancer Center…

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. He is a member of the Mayo Clinic Board of Governors and Board of Trustees. He earned his MD at Universidad Anahuac, Mexico. He completed a residency in Internal Medicine at the University of Miami, FL, and a fellowship in Hematology and Medical Oncology at Mayo Graduate School of Medicine, Rochester, MN. He was named a Clinical Investigator for the Damon Runyon Cancer Research Fund. Dr Fonseca’s practice and research have focused on the diagnosis and treatment of plasma cell disorders. He leads the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr Fonseca has led his team of researchers to better understand the genetic nature of malignant plasma cells, real world evidence analysis, myeloma bone disease, prognostic markers, pharmacoeconomics and development of new therapies for the disease. He is an active participant and leader of myeloma clinical trials. He also has served as consultant to multiple companies including AbbVie, Adaptive Biotechnologies, Amgen, Apple, BMS, GSK, Janssen, Karyopharm, Pfizer, Regeneron, and Sanofi. He is a member of the Scientific Advisory Board of Caris Life Sciences, Ryght, Fortvita and Xenagos. He is a member of the Board of Directors for Antengene. He holds the patent for FISH prognostication in myeloma. He has over 400 peer reviewed publications with an associated H index of 135 with 73,278 citations (Google Scholar October 2026). Throughout his training and career, Dr Fonseca has received numerous awards and honors, including the Damon Runyon Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. He is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. He was awarded in 2023 the Cyril-Rozman prize by the Spanish Society of Hematology and Hematotherapy. He was awarded a Doctor honoris causa by the Universidad de San Pablo, Argentina in February 2023. He was inducted into the Giants of Cancer Care in 2024. Dr Fonseca holds memberships and has served in positions for organizations such as the ASCO, ASH and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE, CPTAC U01), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, and the Damon Runyon Cancer Research Fund, Paula and Rodger Riney Foundation and others. Dr Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor.
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Transcript